The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) is now priced at $4.52 and the shares are 0.05 points up or 1.12% higher compared to its previous closing price of $4.47. The stock had 105577 contracts set over the past session. LIFE shares’ daily volume is compared to its average trading volume at 112076 shares. However, it has a float of 7.02 million and although its performance was 0.22% over the week, it’s one to watch.LIFE share price recently placing at $4.37 to $4.7299. However, some brokerage firms have priced the stock below the average, including one that has called $8.
The shorts are climbing into the aTyr Pharma, Inc. stock, with the latest data on short interest released on June 30, 2020, showing that short interest numbers in the LIFE shares have risen. Short interest in the stock represents just 0.62% of its float, but the volume has raised by 5173. The volume of shorted shares rised to 43546 from 38373 shares over the last two weeks. The average intraday trading volume has been 149455 shares, which means that days to cover moved to roughly 1.
In the last trading session, aTyr Pharma, Inc. (NASDAQ:LIFE) raised by $0.01 over the week and gained $0.41 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $7.62. The stock recorded its established 52-week high on 01/06/20.
Since 03/19/20, the stock has traded to a low of $2.13 at 112.21%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 2.32. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, aTyr Pharma, Inc.’s two-week RSI is 51.7. This suggests that the stock is neutral at the moment and that LIFE shares’ price movement remains stable. The stochastic readings are equally revealing at 56.42% meaning the LIFE share price is currently in neutral territory.
The technical chart shows that the LIFE stock will likely settle at between $4.71 and $4.9 per share. However, if the stock dips below $4.35, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $4.18.
Currently, the stock is trading in the green of MACD, with a reading of 0.08. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned LIFE a rating of Buy in their intiating review released on March 04. Oppenheimer analysts see the stock as a Outperform with a target price of $8 in a flash note released to investors on March 02 initiating covering the stock. JP Morgan seeing the stock struggling downgraded it from Neutral to Underweight on February 14.
The average rating for the LIFE equity is 2 and is currently gathering a bullish momentum. Of 3 analysts tracking aTyr Pharma, Inc. polled by Reuters, 1 rated LIFE as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Zacks Consensus Estimate forecasts that the current-quarter revenues for aTyr Pharma, Inc. (NASDAQ:LIFE) will decrease by about -95.04%, which will see them reach $400 million. The company’s full-year revenues are, however, expected to diminish by about -97.82%, down from $422 million to $9.18 million. LIFE’s expected adjusted earnings should drop almost -59.44% to end up at -$0.73 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -66.86% to record -$2.33/share.